Company Statement: Reckitt Benckiser petition to FDA rejected
MLex Summary: Reckitt Benckiser Pharmaceuticals has received a rejection to its petition to the U.S. Food and Drugs Administration asking that the Administration not accept applications of drugs buprenorphine-containing products used to...To view the full article, register now.
Already a subscriber? Click here to view full article